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Lessons Learned During Recent Vaccine Filings

Outline
y Regulatory challenges with vaccines
y Managing Risk – the importance of planning
y Approach to agency feedback during development
y Managing activities during regulatory review
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Background

y During 2004-2005 Merck submitted applications
for marketing approval for 4 new vaccines
− PROQUAD®
− ROTATEQ ®
− ZOSTAVAX®
− GARDASIL®

y Global regulatory review
− Overlapping review cycles
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Challenges in vaccine development

y Manufacturing complexity
y Integration of clinical, process and analytical development
y Relatively long development cycle
− New information may impact development plans
y Changing regulatory environment
− Increasing emphasis on safety
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Managing Regulatory Risk
The Importance of Planning
y Planning during development
− Identifying key regulatory issues
− Developing a plan to address these issues

y Planning the preparation of the file
− Well-organized dossier
− Ensuring key label statements are supported

y Planning for activities during review
− Pre-filing checklist
− Challenge of global simultaneous submissions
5

Identifying key regulatory questions/issues

What does the efficacy evaluation need to address?
y Risk/benefit - sufficient benefit to justify use in healthy?
y Precision of estimate – lower bound
y Non-inferiority - clinically relevant equivalence margins
− How well understood is the quantitative relationship between
immunogenicity and efficacy?
− Potential impact of decrease in efficacy on transmission
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Identifying key regulatory questions/issues

What does the safety evaluation need to address?
y Risk/benefit - sufficiently safe to justify use in healthy?
y Evaluation of uncommon AEs – power to detect
− What is a signal? Issue of multiple comparisons

y New information may change the scope/focus of the
safety evaluation
− Rotavirus vaccines and intussusception

y Questions related to new technology
− New cell substrates – new adventitious agents
− Novel adjuvants – cascade effects? autoimmunity?
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Identifying key regulatory questions/issues

y “Non-traditional” efficacy measures
− Novel endpoints may be less familiar
− Need for agreement on how to measure efficacy
y What is clinically relevant?
y Endpoint validation
y Surrogacy

− How to communicate to physicians and patients
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Regulatory feedback during development
y Refer to guidance when possible
y Identify questions for agency feedback
y Develop proposals for concurrence
y Some questions may require iterative discussion as data
become available
y There may not be pre-defined answers to some questions
− Potential need for broader discussion/input
y Guidance may change as science evolves
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Regulatory feedback during development
y Procedural aspects
− Formal feedback
y US: PDUFA meetings, Special Protocol Assessment
y EU: Scientific Advice

− Informal feedback
y May be particularly useful for preclinical and CMC questions
which are “non-standard”
y May be useful in helping formulate questions for Scientific
Advice
y Workload issues at agencies – being judicious with what
questions to ask
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Regulatory feedback during development
Examples of items for concurrence
y Clinical data supporting licensure
− Study population
− Safety database
− Efficacy endpoints
y Endpoint validation
y Clinical assay validation

− Criteria for success
− Concomitant use data
− Demonstration of manufacturing consistency
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Regulatory feedback during development
Examples of items for concurrence
y Analytical Development Plans
− Role/utility of characterization dependent on
whether the product is well-characterized
− Rationalizing analytical development plan
y Purpose of each test, supporting data and interpretation as
to why test is appropriate for chosen purpose
y Integration of analytical, process and clinical development

− Product specifications versus characterization
− Comparability protocols
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Managing Regulatory Risk
The Importance of Planning
y Planning during development
− Identifying key regulatory issues
− Developing a plan to address these issues

y Planning the preparation of the file
− Well-organized dossier
− Ensuring key label statements are supported

y Planning for activities during review
− Pre-filing checklist
− Challenge of global simultaneous submissions
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Pre-submission preparations
y Pre-submission meetings
− Update agencies on phase III results
− Status and timing of ongoing studies
− Agreement on content/format of application
y High level – not a “pre-review” of data
y Electronic submissions considerations

− Workload planning for agency
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Pre-submission preparations
y Manufacturing
− Readiness for inspections
− Detailed review of facility information will be
conducted by CBER onsite during PAI

y Batch release
− Interactions with agencies performing batch
release
− Discussion and selection of OMCL and TOI (EU)
− Establish release assays prior to launch
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Pre-submission preparations
y Risk Management Planning
− Early planning for post-licensure studies
y Evaluate product use in “real-world” setting
y Detection of less common adverse events

− Linked databases
y Important tool for evaluating rare AEs
y Finite number of venues/investigators (who may have other
commitments)
y Local institutional/operational factors may impact on protocol
design and timing – critical issue for PMC timing/compliance
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Advisory Committee Meetings
y Routinely convened for most new vaccines
− Under FDAAA, FDA needs to justify not having an ACM
y External consultants asked by FDA to opine on adequacy
of evidence supporting safety/efficacy
− AC may recommend additional studies pre- or post-licensure

y Restrictive Conflict of Interest requirements
− Challenges identifying experts without conflicts

y Need to anticipate likely questions and prepare for these
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Summary/Conclusion

y Planning is key
y Use agency feedback during development to better
understand the key issues for the benefit-risk evaluation
y Some questions may require a broader discussion
y New information may impact on requirements
y The environment is changing
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